Clinical Trial

Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration

Study acronym: PRIMAlia
Recruiting
View on ClinicalTrials.gov →
Summary
The objective of this study is to evaluate the efficacy and safety of the PRIMA Products in participants with inherited retinal degeneration affecting the macula (including but not limited to Stargardt disease, and Retinitis Pigmentosa). Eligible participants will be implanted with the PRIMA Stim implant. The participants will be assessed with various visual function and functional vision tests at defined timepoints throughout the clinical investigation with the PRIMA Products. The purpose of this study is to gather enough clinical data to support the clinical evaluation required for the continuous development to improve the PRIMA Products.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-24.
Status change: Not Yet Recruiting → Recruiting 2026-03-27
Trial Details
NCT Number NCT07266584
Lead Sponsor Science Corporation
Conditions Stargardt Disease, Retinitis Pigmentosa (RP), Inherited Retinal Degeneration
Enrollment 5 participants
Start Date 2026-03-12
Primary Completion 2029-03-01 (estimated)
Study Completion 2031-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-02